AcelRx Pharmaceuticals Inc To Discuss its Recently Acquired Late-stage Product Candidate, Niyad™ Transcript
Good afternoon, and welcome to the AcelRx KOL event. (Operator Instructions) We will be hosting 2 Q&A sessions today, once after Dr. Chawla and once at the end of all the presentations. (Operator Instructions) I would now like to turn the call over to your host, Vince Angotti, Chief Executive Officer of AcelRx. Please go ahead, Vince.
Thanks, Sara, and thank you to the LifeSci for helping organize today's presentation and all of you who have tuned in with an interest in AcelRx Pharmaceuticals and the nafamostat program. We much appreciate your interest.
Next slide, please. As always, before we begin, I'll remind you that today's session may include forward-looking statements that involve risks and uncertainties of our business, and I'd encourage you to refer to our SEC filings for additional information.
Next slide, please. So most of you have known AcelRx as an acute pain company for the last
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
